Visionary Ventures, an Aliso Viejo, California-based venture capital firm, closed Visionary Venture Fund II, at $114m.
The fund was supported by existing and new Ophthalmology and Optometry Key Opinion Leader (KOL) limited partners.
Visionary Ventures is a venture capital firm that invests in promising life sciences and ophthalmology startups.
Leading Visionary Fund II is Managing Partner, Jeffry Weinhuff and Principal, Garrett Hamontree along with Venture Partner Daniel Gil, PhD. The firm is supported by industry leaders on the Investment Advisory Committee, including Richard Lindstrom, MD; Ehsan Sadri, MD; Farrell Tyson, MD; Bill Carpou; Robert Avery, MD; and Jeffry Weinhuff.
Fund II backed companies include Tarsus Pharmaceuticals, Orasis Pharmaceuticals, and TearClear. Past marquee Visionary investments include IanTech, RxSight, and Tear Film Innovations.
FinSMEs
27/03/2021